Posted by Michael Wonder on 22 Mar 2023
Nivolumab in combination with chemotherapy for the neo-adjuvant treatment of patients with resectable non-small-cell lung cancer
22 March 2023 - NICE has published evidence based recommendations on the use of nivolumab (Opdivo) in combination with chemotherapy for the neo-adjuvant treatment of adults with resectable non-small-cell lung cancer.
Nivolumab, when used in combination with chemotherapy, is recommended as an option for the neo-adjuvant treatment of adults with resectable (tumours at least 4 cm or node positive) non-small-cell lung cancer.
